Skip to main content
Publications
Grivas P, Barata P, Moon H, Gupta S, Hutson T, Sternberg CN, Brown JR, Dave V, Downey C, Shillington AC, Katzenstein HM, Kirker M, Hanson S, Liu FX, Morris V, Bhanegaonkar A, Sonpavde GP. Avelumab first-line maintenance for locally advanced or metastatic urothelial carcinoma: results from the Real-world US PATRIOT-II Study. Clin Genitourin Cancer. 2024 Dec;22(6):102238. doi: 10.1016/j.clgc.2024.102238
Meraviglia-Crivelli D, Villanueva H, Zheleva A, Villalba-Esparza M, Moreno B, Menon AP, Calvo A, Cebollero J, Barainka M, de Los Mozos IR, Huesa-Berral C, Pastor F. IL-6/STAT3 signaling in tumor cells restricts the expression of frameshift-derived neoantigens by SMG1 induction. Mol Cancer. 2022 Nov 28;21(1):211. doi: 10.1186/s12943-022-01679-6
Stattin P, Westerberg M, Franck Lissbrant I, Hjalm-Eriksson M, Kjellman A, Ullen A, Vassilev Z, Sandstrom P, Weinrib R, Martinez D, Garcia de Albeniz Martinez X. Real world outcomes in patients with metastatic, castration-resistant prostate cancer treated with radium-223 in routine clinical practice in Sweden. Clin Genitourin Cancer. 2022 Sep 9;S1558-7673(22):00194-X. doi: 10.1016/j.clgc.2022.09.002